Aripiprazole orally disintegrating tablets are effective and useful for the treatment of schizophrenia, among others. The mechanism of action of aripiprazole orally disintegrating tablets is currently thought to be mediated through partial agonism at D2 and 5-HT1A receptors and antagonism at 5-HT2A receptors.This product is primarily used for the treatment of schizophrenia. The efficacy of aripiprazole for the treatment of schizophrenia was established in short-term (4- and 6-week) controlled trials in patients with schizophrenia. Physicians who choose aripiprazole for long-term treatment should periodically reassess the long-term efficacy of the drug in individual patients. Possible adverse reactions to the administration of aripiprazole orally disintegrating tablets include headache, weakness, accidental injury, and peripheral edema. Aripiprazole Oral Disintegrating Tablets are contraindicated in those who are allergic to its ingredients, in those with cardiovascular disease, and in patients with a history of epilepsy. Women taking aripiprazole stop breastfeeding, should not be combined with other central nervous system drugs and ethanol. If you need to use this drug, please consult a professional doctor, follow the doctor’s instructions, rational use of medication.